Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAna Saus CarreresMAMario ArnaoEPElena Fernández Poveda

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals talquetamab shows high overall response rates in BCMA exposed and naïve multiple myeloma patients, suggesting efficacy in treatment sequencing.

Key Points

  • To examine the impact of previous BCMA exposure on treatment outcomes with talquetamab in multiple myeloma patients.
  • Conducted a retrospective, observational study with patient data from 68 centers in Spain.
  • Included adult patients with relapsed/refractory multiple myeloma who started TAL monotherapy.
  • Analyzed outcomes of talquetamab in BCMA exposed and BCMA naïve patients.
  • Overall response rates were 89% for BCMA exposed patients and 81% for BCMA naïve patients.
  • Progression-free survival was similar between groups, with 9.9 months for BCMA exposed and 8.4 months for naïve.
  • Significant differences noted in prior treatment lines and time from diagnosis between groups.

Cite This Study

Carreres et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df43https://doi.org/10.1182/blood-2025-2272
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.2026
  2. 2Talquetamab outcomes from practice outside of clinical trials: The bital study2025
  3. 3Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations2025
  4. 4P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS2026
  5. 5Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025